Post-Acute Withdrawal: Why Months Two Through Twelve Are the Hardest Part of Recovery

Your son came home from thirty days of treatment in March. He slept badly for a week, ate everything in the kitchen, and then went quiet. By May he was flat and irritable, sleeping until noon, unable to finish a job application, and telling you he felt nothing at all. Nothing in the discharge plan mentioned this. The program talked about triggers, meetings and a relapse plan. Nobody explained that the second, third and sixth months after the last drink or dose can be harder than the first week.

That experience has a name — post-acute withdrawal, also called protracted withdrawal — and it is one of the most common reasons families conclude that treatment did not work. This guide covers what the research actually shows, how the timeline differs by substance, what these symptoms are easily confused with, and what helps.

What Post-Acute Withdrawal Actually Is

Post-acute withdrawal is the clinical shorthand for symptoms that outlast the acute withdrawal syndrome. It is not a formal DSM-5 diagnosis. DSM-5 describes withdrawal for each substance as a time-limited syndrome; post-acute withdrawal is the name clinicians and researchers use for what continues after that window closes. (For the acute phase itself — the first days, and which substances require medical supervision — see our guide to detox and withdrawal management.)

A 2023 systematic review of protracted alcohol withdrawal describes the syndrome in three phases — acute, early and protracted — and notes that the protracted phase can produce symptoms persisting for weeks, months or even years after drinking stops. The symptoms families describe most often are:

• Craving that comes in waves, often triggered by time of day, places or arguments
• Sleep disturbance — difficulty falling asleep, waking at 3 a.m., unrefreshing sleep
• Anhedonia — food, music, sex, hobbies and people all feel muted
• Mood instability, irritability, and anxiety that seems to have no object
• Cognitive fog — poor concentration, word-finding problems, indecision
• Stress sensitivity, where small problems feel unmanageable

The biology is not mysterious. George Koob's work on opioid addiction describes hyperkatifeia: an intensification of the negative emotional and motivational symptoms of withdrawal that can extend into protracted abstinence. The brain's stress systems — corticotropin-releasing factor, dynorphin, norepinephrine, hypocretin, vasopressin, glucocorticoids and neuroimmune signalling — are recruited during heavy use and stay sensitized afterwards. In plain terms, the reward system is still recalibrating while the stress system is running hot. Feeling flat, irritable and easily overwhelmed is a predictable pharmacological state, not a character flaw or a lack of willingness.

How Long Does It Last?

There is no single number, and anyone who offers one is guessing. The honest version, drawn from the sources used in this guide:

• Alcohol: craving improves steeply across the first month and then plateaus, while sleep complaints can persist for months.
• Opioids: the acute phase peaks at 24 to 48 hours and subsides in about a week, but NIDA notes that some people show persistent withdrawal signs for many months.
• Stimulants: the withdrawal literature describes a late protracted phase beyond four weeks, with low mood and craving lasting weeks longer.
• Benzodiazepines: persistent symptoms after the first week may last for many months.
• Cannabis: irritability and insomnia typically run for weeks rather than days.

Across substances, the pattern is a steep early improvement followed by a long, uneven tail that most descriptions place inside the first year.

Why Month Two Is Often Harder Than Week One

Acute withdrawal is visible and staffed. Someone is monitoring vital signs, adjusting medication, and telling you both that the first week will be rough. Post-acute withdrawal is invisible and unscheduled. It arrives after discharge, when the structure, the daily check-ins, the peer group and the clinical attention all stop at once.

Three findings explain why that timing is so damaging.

Craving falls quickly, then flattens. In the pooled data from 37 studies using the Obsessive Compulsive Drinking Scale, scores fell from 24.2 at baseline to 18.8 at one week and 10.3 at one month — then barely moved, reaching 9.7 at three months. The steep improvement happens while the person is still in treatment. What follows is a long plateau, and a plateau feels like failure when you were promised a slope.

Treatment changes the speed, not the direction. Untreated participants in the same review declined from 25.3 to 13.9 at one week, then sat at 13.2 at one month and 11.4 at three months. Treated participants reached 8.7 by one month. The review's own conclusion is that a pharmacological approach can compress into roughly three weeks what otherwise takes close to six months. That is a strong argument for staying in care — and a warning about what happens when care ends at day 28.

Sleep does not follow the craving curve. In the four studies that measured sleep with the Epworth Sleepiness Scale, scores were essentially flat: 7.3 at baseline, 7.3 at one week, 7.2 at one month, 7.1 at three months. Sleep complaints are among the last things to resolve, which matters because poor sleep independently predicts return to use. A person can have genuinely reduced craving and still be sleeping three hours a night.

Put together, the message the person receives from their own body is "this is not getting better," at exactly the moment the professional support thins out.

The Timeline, Substance by Substance

The word "withdrawal" covers different physiology in different substances, and the post-acute phase differs in length, shape and risk. Generalising from one to another is how families end up with the wrong expectations.

Alcohol

Craving declines fastest in the first month and then plateaus, as the numbers above show. Sleep problems persist well past that point. The other finding that matters clinically is kindling: withdrawal severity tends to increase after repeated withdrawal episodes, a phenomenon supported by both clinical and experimental evidence. The same review of that literature argues that even patients with mild withdrawal should be treated aggressively, because kindling may contribute to relapse risk and to alcohol-related brain damage and cognitive impairment.

The practical implication is uncomfortable but important: a fifth detox is not a repeat of the first. Each episode tends to be harder than the one before, which is one reason medically supervised withdrawal and a plan for never repeating it matter more than getting through it quickly.

Opioids

NIDA's clinical description is precise about the acute phase: withdrawal begins within hours of the last dose, peaks between 24 and 48 hours, and subsides after about a week — but some people show persistent withdrawal signs for many months. The acute symptoms are the familiar ones: restlessness, muscle and bone pain, insomnia, diarrhea, vomiting, cold flashes, leg movements.

The months-long part is the hyperkatifeia described above: dysphoria, anxiety, increased pain sensitivity and a flat inability to feel pleasure. This is the strongest argument against tapering medication in the third week of treatment because the person "seems fine." Methadone and buprenorphine hold the system stable while it recalibrates; removing that support during the protracted phase is how a stable patient becomes a returning patient.

There is also a safety point families are rarely told. Tolerance falls during abstinence. A person who returns to use after months away, at their old dose, is at elevated risk of overdose. Naloxone in the house is not an overreaction at any stage of this timeline.

Stimulants

A 2023 review of psychostimulant withdrawal states that a majority of people who use methamphetamine or cocaine experience withdrawal on abstinence, and it divides the course into phases: acute (the first week), early protracted (weeks 2 to 4) and late protracted (beyond four weeks). The characteristic picture is a crash — exhaustion and long sleep, then depression, anhedonia and craving that can last weeks.

The same review is candid that the medication evidence is thin. Mirtazapine, naltrexone and bupropion show potential for methamphetamine withdrawal, and repetitive transcranial magnetic stimulation has been studied; topiramate shows mixed results for cocaine. Overall, the authors describe an inconsistent signal for both biomedical and behavioural treatments. For families, the honest takeaway is that stimulant post-acute withdrawal is mostly managed with time, sleep, structure and behavioural treatment rather than a prescription.

Benzodiazepines

The classic description of protracted benzodiazepine withdrawal notes that symptoms in the first week after stopping tend to merge into more persistent symptoms that may last for many months. Tolerance develops unevenly across brain systems and may be slow to reverse. The prolonged symptoms include anxiety — which the author suggests may partly reflect a learning deficit imposed by the drug — along with a variety of sensory and motor neurological symptoms.

Two things follow. First, benzodiazepines are the one class in this list where abrupt discontinuation can be dangerous, so any taper belongs to a prescriber, not to a family decision — our benzodiazepine tapering guide covers what a safe taper looks like. Second, the months-long anxiety after a slow taper is expected, which is different from saying the taper failed.

Cannabis

NIDA notes that withdrawal can occur after stopping or significantly reducing heavy, long-term cannabis use even without a cannabis use disorder; one study estimated that about 12 percent of people who use cannabis frequently experience withdrawal. Symptoms include anger and irritability, aggression, nervousness or anxiety, restlessness, decreased appetite and weight loss, depressed mood, insomnia, unsettling dreams, headaches, sweating, abdominal pain and tremor.

There are currently no FDA-approved medications for cannabis use disorder or for medically assisted withdrawal. The post-acute phase is largely irritability, insomnia and low mood over weeks, and behavioural treatment is the mainstay.

What Post-Acute Withdrawal Is Not

The syndrome is real, which makes it easy to over-apply. Five distinctions matter, because each one changes what you do next.

It is not relapse. Return to use is a separate event with its own response. Treating every bad week as a relapse damages trust; missing an actual return to use because it was filed under "PAWS" is worse. Ask directly and calmly rather than inferring from mood.

It is not a substitute diagnosis for an untreated psychiatric condition. Depression, generalised anxiety, PTSD and ADHD are common alongside substance use disorders, and they do not resolve just because someone stopped drinking. If low mood, panic or inability to function is severe or worsening rather than slowly improving, that needs assessment and treatment, not patience.

It is not the explanation for every physical symptom. Persistent fatigue, weight loss, palpitations or cognitive change can come from thyroid disease, anaemia, sleep apnoea, chronic pain, liver disease or the side effects of prescribed medication. Months of symptoms deserve a physical work-up, not just an addiction explanation.

It is not a reason to stop medication early. The protracted phase is precisely when MAT earns its keep. Decisions about tapering belong to the prescriber and the patient, after a stable period, not to a difficult month.

It is not permanent — and it is not infinite. Most descriptions have symptoms improving gradually across the first year. Symptoms that are worse at month ten than at month four are not a normal PAWS curve, and they are a reason to go back to the clinician.

What Actually Helps

There is no medication that switches post-acute withdrawal off. What the evidence supports is a set of unglamorous interventions that make the months survivable and reduce the chance of a return to use.

Treat the sleep problem specifically. Consistent wake time, no alcohol or cannabis as a sleep aid, and cognitive behavioural therapy for insomnia (CBT-I) rather than sedatives, which carry their own dependence risk in exactly this population. Our guide to sleep in early recovery covers the practical version.

Keep the medication that is working. Continuing methadone or buprenorphine through the protracted phase is a clinical decision with a strong rationale (see our medication-assisted treatment guide); stopping because the person feels better is a common and avoidable mistake.

Use the medications that exist for craving. Naltrexone and acamprosate reduce craving and support abstinence in alcohol use disorder. They are not cures, and they are underused.

Build structure before motivation arrives. Work, school, volunteering, a fixed wake time, exercise at the same hours. Boredom and unstructured afternoons are high-risk territory, and motivation tends to follow activity rather than precede it.

Stay in behavioural treatment. CBT, contingency management and mutual-aid groups all have evidence behind them, and the weeks when someone feels flat are exactly when attendance collapses. A written relapse prevention plan built during a good week is worth more than one built during a crisis.

Be sceptical about supplements. The market for "brain recovery" products is large and the evidence is thin. Nothing sold online has been shown to shorten protracted withdrawal. That money is better spent on therapy sessions and transport to meetings.

Track it instead of arguing about it. A two-minute weekly log — sleep hours, mood from 1 to 10, craving from 1 to 10, any return to use — turns a vague "I feel terrible" into a trend you can show a clinician. It also gives the person evidence of progress on days when progress is invisible.

What Families Can Do — and What to Stop

Families usually get two pieces of advice about this phase, and both are wrong: watch them constantly, or detach entirely. The useful position is in between.

Ask about today, not about use. "How did you sleep? What is today looking like?" gets more information than "Are you using again?" and does not trigger the defensive script.

Protect sleep and routine over lectures. A quiet house at 11 p.m. and a shared breakfast do more for the protracted phase than a conversation about potential.

Lower the emotional temperature. Conflict is a trigger, and a household that is either auditing or erupting every evening is providing daily exposure. This is not about avoiding hard conversations; it is about having them once, calmly, rather than continuously.

Do not score every mood. A flat Tuesday is not evidence of relapse, and a good week is not proof of recovery. Both readings put pressure on a person whose internal state is not yet reliable.

Keep the door open during the bad weeks. Ultimatums issued at month four, in the middle of a predictable PAWS wave, are often the thing that ends a treatment episode that would otherwise have held.

Look after yourself on a schedule. Family support groups and your own therapist are not luxuries in this phase; they are what keeps the household stable enough for the person to recover in. Our guide to self-care for family members treats it as a plan rather than a slogan.

Red Flags That Mean Call a Clinician This Week

Most of this timeline is managed at home with outpatient support. These are not:

• Any talk of suicide, hopelessness or not wanting to be here. Call or text 988 immediately. Do not wait for the next appointment.
• A return to use, especially after a period of abstinence, because tolerance has dropped and overdose risk is elevated. Have naloxone in the house and know how to use it.
• Symptoms that are worse at six to twelve months than they were at two. That is not the expected curve.
• New neurological symptoms — numbness, tremor, confusion, seizures — which need medical assessment, not an addiction explanation.
• Inability to eat, sleep or work for more than a week, or rapid weight loss.
• Severe depression with slowing, withdrawal from everyone, or loss of basic self-care.

The Bottom Line

Post-acute withdrawal is the part of recovery that treatment brochures leave out and families discover alone. It is real, it is expected, it varies by substance, and it improves — but on a slower schedule than anyone promised. Craving drops fast and then plateaus; sleep lags behind; the flat, irritable, foggy months are the brain's stress and reward systems recalibrating rather than evidence that treatment failed.

The families who get through it well tend to do the same things: they keep the person in care past the discharge date, they protect sleep and structure, they treat mood changes as information rather than verdicts, and they go back to a clinician when the curve turns the wrong way. If you are in the middle of this and unsure whether what you are seeing is the expected phase or something that needs attention, call the SAMHSA National Helpline at 1-800-662-4357 — it is free, confidential and available 24 hours a day — or use FindTreatment.gov to locate an outpatient provider who can assess it properly.